Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05030441
Study type Interventional
Source Washington University School of Medicine
Contact Kelly Bolton, M.D.
Phone 314-273-5711
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date November 30, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04902833 - Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Recruiting NCT04102423 - CHIP/CCUS Natural History Protocol
Recruiting NCT03418038 - Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or Clonal Cytopenia of Undetermined Significance Phase 2